Investors

Press Releases

Date Title Media
08/08/22 Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
07/13/22 Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences
07/06/22 Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer
06/23/22 Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma
06/14/22 Calithera Biosciences Announces 1-for-20 Reverse Stock Split
05/17/22 Calithera to Present at the H.C. Wainwright Global Investment Conference
05/10/22 Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
05/03/22 Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
04/08/22 Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds
03/31/22 Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
03/30/22 Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock
03/29/22 Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock
03/24/22 Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022
03/08/22 Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting
02/16/22 Calithera to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
01/05/22 Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference